Chinese mainland drugmaker Jiangsu Hengrui Pharmaceuticals Co filed to list its shares in the Hong Kong Special Administrative Region, adding to the growing number of publicly traded mainland firms looking to have their stock trade in the financial hub.

ALSO READ: Retail traders seek nearly $60b for toymaker’s HK IPO

Mainland companies whose shares already trade in the mainland are betting that adding a Hong Kong listing would make it easier for foreign funds to invest in them. Hengrui’s share sale could fetch at least $2 billion, people familiar with the situation have said.

Morgan Stanley, Citigroup Inc and Huatai Securities Co are arranging the deal.